Biocad Acellbia (Rituximab)

Acellbia (Rituximab) - the Russian medicine on the basis of monoclonal antibodies, a bioanalogue. Indications to application: the nekhodzhkinsky lymphoma, chronic limfoleykoz, rheumatoid arthritis, granulematoz and microscopic poliangiit Wegener.

2020: Obtaining the registration certificate in Bosnia and Herzegovina

On March 30, 2020 Biocad reported that two of its medicines, Acellbia (MNN: rituximab) and Herticad (MNN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration is received with assistance of the partner of ICM d.o.o and 5 years work. The first deliveries are going to start in June, 2020.

Registration processes started in December, 2018. Thorough examination of the documentary file of medicines and quality of samples of medicines was during this time carried out. According to the legislation, the first commercial series of medicine for implementation is for this purpose used. As a result the circulation of medicines Agency and medical products (Drug Agency) made the positive decision on registration of two medicines: rituximab (Acellbia) and trastuzumab (Herticad).

Now BIOCAD will be engaged in the organization of deliveries, and ICM d.o.o will be responsible for implementation of medicines in Bosnia and Herzegovina. Distribution is going to be carried out mainly through the state tenders and wholesales to the oncological centers. The start of sales and pricing in many respects depend on tenders, however at approval of the partner of delivery will be started in 2020.

Nikola Rosich, the CEO of ICM d.o.o expressed joy that registration of the Russian medicines took place successfully.

Their entry into the market of Bosnia and Herzegovina will allow to save considerably means in Fund of health insurance, and patients at the same time will be able to receive more effective treatment — the strategic partner of BIOCAD company in the region added.

Analyzing international markets for start of medicines, we see that our products are demanded. Therefore in parallel we conduct registration processes in the different countries of Europe. For example, after successful registration in Bosnia and Herzegovina, we with the same partner are going to get access to the market of Serbia. These are important steps on the way to one of key tasks of our company – to make high-quality therapy available worldwide, told Dmitry Morozov, the CEO of BIOCAD